|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei J, Wu ND and Liu BR: Regional but
fatal: Intraperitoneal metastasis in gastric cancer. World J
Gastroenterol. 22:7478–7485. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomassen I, van Gestel YR, van Ramshorst
B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE and de Hingh IH:
Peritoneal carcinomatosis of gastric origin: a population-based
study on incidence, survival and risk factors. Int J Cancer.
134:622–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saladino E, Fleres F, Mazzeo C, Pruiti V,
Scollica M, Rossitto M, Cucinotta E and Macri A: The role of
prophylactic hyperthermic intraperitoneal chemotherapy in the
management of serosal involved gastric cancer. Anticancer Res.
34:2019–2022. 2014.PubMed/NCBI
|
|
5
|
Chau I, Norman AR, Cunningham D, Waters
JS, Oates J and Ross PJ: Multivariate prognostic factor analysis in
locally advanced and metastatic esophago-gastric cancer-pooled
analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol. 22:2395–2403. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maeda H, Kobayashi M and Sakamoto J:
Evaluation and treatment of malignant ascites secondary to gastric
cancer. World J Gastroenterol. 21:10936–10947. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishigami H, Fujiwara Y, Fukushima R,
Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y,
Amagai K, et al: Phase III trial comparing intraperitoneal and
intravenous paclitaxel plus S-1 Versus Cisplatin Plus S-1 in
patients with gastric cancer with peritoneal metastasis: PHOENIX-GC
trial. J Clin Oncol. 36:1922–1929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alshuwaykh O, Cheung A, Goel A, Kwong A,
Dhanasekaran R, Ghaziani TT, Ahmed A, Daugherty T, Dronamraju D,
Kumari R, et al: Clinical characteristics and outcomes in those
with primary extrahepatic malignancy and malignant ascites. BMC
Gastroenterol. 22:4102022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahmed N and Stenvers KL: Getting to know
ovarian cancer ascites: Opportunities for targeted therapy-based
translational research. Front Oncol. 3:2562013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaufman JL: Care of patients with ascites.
N Engl J Med. 330:1827author reply 1828. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim S, Kim B and Song YS: Ascites
modulates cancer cell behavior, contributing to tumor heterogeneity
in ovarian cancer. Cancer Sci. 107:1173–1178. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ito M, Nakano M, Ariyama H, Yamaguchi K,
Tanaka R, Semba Y, Sugio T, Miyawaki K, Kikushige Y, Mizuno S, et
al: Macrophages are primed to transdifferentiate into fibroblasts
in malignant ascites and pleural effusions. Cancer Lett.
532:2155972022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vokurka M, Lacina L, Brabek J, Kolar M, Ng
YZ and Smetana K Jr: Cancer-associated fibroblasts influence the
biological properties of malignant tumours via paracrine secretion
and exosome production. Int J Mol Sci. 23:9642022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Y, Qi C, Liu X, Zhang C, Gao J, Wu Y,
Yang J, Zhao Q, Li J, Wang X and Shen L: Malignant ascites-derived
exosomes promote peritoneal tumor cell dissemination and reveal a
distinct miRNA signature in advanced gastric cancer. Cancer Lett.
457:142–150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xuan Y, Wang H, Yung MM, Chen F, Chan WS,
Chan YS, Tsui SK, Ngan HY, Chan KK and Chan DW: SCD1/FADS2 fatty
acid desaturases equipoise lipid metabolic activity and
redox-driven ferroptosis in ascites-derived ovarian cancer cells.
Theranostics. 12:3534–3552. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al-Marzouki L, Stavrakos VS, Pal S,
Giannias B, Bourdeau F, Rayes R, Bertos N, Najmeh S, Spicer JD,
Cools-Lartigue J, et al: Soluble factors in malignant ascites
promote the metastatic adhesion of gastric adenocarcinoma cells.
Gastric Cancer. 26:55–68. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Milliken D, Scotton C, Raju S, Balkwill F
and Wilson J: Analysis of chemokines and chemokine receptor
expression in ovarian cancer ascites. Clin Cancer Res. 8:1108–1114.
2002.PubMed/NCBI
|
|
18
|
Puiffe ML, Le Page C, Filali-Mouhim A,
Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM and
Mes-Masson AM: Characterization of ovarian cancer ascites on cell
invasion, proliferation, spheroid formation, and gene expression in
an in vitro model of epithelial ovarian cancer. Neoplasia.
9:820–829. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin T, Wang G, He S, Shen G, Su C, Zhang
Y, Wei X, Ye T, Li L, Yang S, et al: Malignant pleural effusion and
ascites induce epithelial-mesenchymal transition and cancer
stem-like cell properties via the vascular endothelial growth
factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic
target of rapamycin (mTOR) pathway. J Biol Chem. 291:26750–26761.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lomelino CL, Andring JT, Mckenna R and
Kilberg MS: Asparagine synthetase: Function, structure, and role in
disease. J Biol Chem. 292:19952–19958. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen X, Cai Y, Lu L, Huang H, Yan H, Paty
PB, Muca E, Ahuja N, Zhang Y, Johnson CH and Khan SA: Asparagine
metabolism in tumors is linked to poor survival in females with
colorectal cancer: A cohort study. Metabolites. 12:642022.
View Article : Google Scholar
|
|
22
|
Zhang B, Dong LW, Tan YX, Zhang J, Pan YF,
Yang C, Li MH, Ding ZW, Liu LJ, Jiang TY, et al: Asparagine
synthetase is an independent predictor of surgical survival and a
potential therapeutic target in hepatocellular carcinoma. Br J
Cancer. 109:14–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Panosyan EH, Lasky JL, Lin HJ, Lai A, Hai
Y, Guo X, Quinn M, Nelson SF, Cloughesy TF and Nghiemphu PL:
Clinical aggressiveness of malignant gliomas is linked to augmented
metabolism of amino acids. J Neurooncol. 128:57–66. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu Q, Wang X, Wang L, Zheng J, Wang J and
Wang B: Knockdown of asparagine synthetase (ASNS) suppresses cell
proliferation and inhibits tumor growth in gastric cancer cells.
Scand J Gastroenterol. 51:1220–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Toda K, Kawada K, Iwamoto M, Inamoto S,
Sasazuki T, Shirasawa S, Hasegawa S and Sakai Y: Metabolic
alterations caused by KRAS mutations in colorectal cancer
contribute to cell adaptation to glutamine depletion by
upregulation of asparagine synthetase. Neoplasia. 18:654–665. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin CY, Sheu MJ, Li CF, Lee SW, Lin LC,
Wang YF and Chen SH: Deficiency in asparagine synthetase expression
in rectal cancers receiving concurrent chemoradiotherapy: Negative
prognostic impact and therapeutic relevance. Tumour Biol.
35:6823–6830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Xu H, Zhang L, Song L, Feng D, Peng
X, Wu M, Zou Y, Wang B, Zhan L, et al: Malignant ascites-derived
organoid (MADO) cultures for gastric cancer in vitro modelling and
drug screening. J Cancer Res Clin Oncol. 145:2637–2647. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
R Core Team (2019), . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: Available from:. http://www.R-project.org/
|
|
30
|
Kanda M and Kodera Y: Molecular mechanisms
of peritoneal dissemination in gastric cancer. World J
Gastroenterol. 22:6829–6840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chiu M, Taurino G, Bianchi MG, Kilberg MS
and Bussolati O: Asparagine synthetase in cancer: beyond acute
lymphoblastic leukemia. Front Oncol. 9:14802019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu Y, Lv F, Zhu X, Wu Y and Shen X: Loss
of asparagine synthetase suppresses the growth of human lung cancer
cells by arresting cell cycle at G0/G1 phase. Cancer Gene Ther.
23:287–294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai DJ, Zhang ZY, Bu Y, Li L, Deng YZ, Sun
LQ, Hu CP and Li M: Asparagine synthetase regulates lung-cancer
metastasis by stabilizing the β-catenin complex and modulating
mitochondrial response. Cell Death Dis. 13:5662022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nishikawa G, Kawada K, Hanada K, Maekawa
H, Itatani Y, Miyoshi H, Taketo MM and Obama K: Targeting
asparagine synthetase in tumorgenicity using patient-derived
tumor-initiating cells. Cells. 11:32732022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gwinn DM, Lee AG, Briones-Martin-Del-Campo
M, Conn CS, Simpson DR, Scott AI, Le A, Cowan TM, Ruggero D and
Sweet-Cordero EA: Oncogenic KRAS regulates amino acid homeostasis
and asparagine biosynthesis via ATF4 and alters sensitivity to
L-Asparaginase. Cancer Cell. 33:91–107. e62018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sandelin A, Alkema W, Engström P,
Wasserman WW and Lenhard B: JASPAR: An open-access database for
eukaryotic transcription factor binding profiles. Nucleic Acids
Res. 32((Database issue)): D91–D94. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng LN, Wen F, Xu P and Zhang S:
Prognostic significance of malignant ascites in gastric cancer
patients with peritoneal metastasis: A systemic review and
meta-analysis. World J Clin Cases. 7:3247–3258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Z, Chen JQ, Liu JL and Tian L: Issues
on peritoneal metastasis of gastric cancer: an update. World J Surg
Oncol. 17:2152019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Anderson NM and Simon MC: The tumor
microenvironment. Curr Biol. 30:R921–R925. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiao Y and Yu D: Tumor microenvironment as
a therapeutic target in cancer. Pharmacol Ther. 221:1077532021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oya Y, Hayakawa Y and Koike K: Tumor
microenvironment in gastric cancers. Cancer Sci. 111:2696–2707.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Asciak R, Kanellakis NI, Yao X, Abd Hamid
M, Mercer RM, Hassan M, Bedawi EO, Dobson M, Fsadni P, Montefort S,
et al: Pleural Fluid Has Pro-Growth biological properties which
enable cancer cell proliferation. Front Oncol. 11:6583952021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheah HM, Lansley SM, Varano Della
Vergiliana JF, Tan AL, Thomas R, Leong SL, Creaney J and Lee YC:
Malignant pleural fluid from mesothelioma has potent biological
activities. Respirology. 22:192–199. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Krejci O, Starkova J, Otova B, Madzo J,
Kalinova M, Hrusak O and Trka J: Upregulation of asparagine
synthetase fails to avert cell cycle arrest induced by
L-asparaginase in TEL/AML1-positive leukaemic cells. Leukemia.
18:434–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stams WA, den Boer ML, Holleman A, Appel
IM, Beverloo HB, van Wering ER, Janka-Schaub GE, Evans WE and
Pieters R: Asparagine synthetase expression is linked with
L-asparaginase resistance in TEL-AML1-negative but not
TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood.
105:4223–4225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zwaan CM, Kaspers GJ, Pieters R, Hählen K,
Janka-Schaub GE, van Zantwijk CH, Huismans DR, de Vries E, Rots MG,
Peters GJ, et al: Different drug sensitivity profiles of acute
myeloid and lymphoblastic leukemia and normal peripheral blood
mononuclear cells in children with and without Down syndrome.
Blood. 99:245–251. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Aslanian AM, Fletcher BS and Kilberg MS:
Asparagine synthetase expression alone is sufficient to induce
l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem
J. 357((Pt 1)): 321–328. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Srivastava S, Jiang J, Misra J, Seim G,
Staschke KA, Zhong M, Zhou L, Liu Y, Chen C, Davé U, et al:
Asparagine bioavailability regulates the translation of MYC
oncogene. Oncogene. 41:4855–4865. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Garrison RN, Kaelin LD, Galloway RH and
Heuser LS: Malignant ascites. Clinical and experimental
observations. Ann Surg. 203:644–651. 1986. View Article : Google Scholar : PubMed/NCBI
|
